Celine Cano

Framlington Place, NE2 4HH
Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications

Targeting DNA-PK: medicinal chemistry insights into small-molecule inhibitor discovery and optimisation.

Targeting DNA-PK: medicinal chemistry insights into small-molecule inhibitor discovery and optimisation.

Journal: RSC medicinal chemistry
Published: February 13, 2026

Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies.

Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies.

Journal: Journal of medicinal chemistry
Published: December 23, 2025

Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy.

Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy.

Journal: Journal of medicinal chemistry
Published: April 01, 2023

A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.

A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs.

Journal: Bioorganic & medicinal chemistry
Published: March 08, 2023

Mapping Ligand Interactions of Bromodomains BRD4 and ATAD2 with FragLites and PepLites─Halogenated Probes of Druglike and Peptide-like Molecular Interactions.

Mapping Ligand Interactions of Bromodomains BRD4 and ATAD2 with FragLites and PepLites─Halogenated Probes of Druglike and Peptide-like Molecular Interactions.

Journal: Journal of medicinal chemistry
Published: November 11, 2022

Advanced approaches of developing targeted covalent drugs.

Advanced approaches of developing targeted covalent drugs.

Journal: RSC medicinal chemistry
Published: July 08, 2022

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor.

Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor.

Journal: Journal of medicinal chemistry
Published: April 25, 2022

An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.

An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-κB-Inducing Kinase.

Journal: Journal of medicinal chemistry
Published: July 02, 2021

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein-Protein Interaction.

Journal: Journal of medicinal chemistry
Published: March 24, 2021

Cyclizations and fragmentations in the alkylation of 6-chloro-5-hydroxy-4-aminopyrimidines with aminoalkyl chlorides.

Cyclizations and fragmentations in the alkylation of 6-chloro-5-hydroxy-4-aminopyrimidines with aminoalkyl chlorides.

Journal: Journal of heterocyclic chemistry
Published: December 10, 2020

Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge.

Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge.

Journal: Diabetes, obesity & metabolism
Published: April 07, 2020

2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase.

2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase.

Journal: RSC medicinal chemistry
Published: March 04, 2020
Showing 1-12 of 43

Last Updated: 09/26/2026